COVID-19 vaccines: Global challenges and prospects forum recommendations.
COVID19
MERS
SARS
Vaccine
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
18
12
2020
revised:
23
02
2021
accepted:
23
02
2021
pubmed:
3
3
2021
medline:
21
5
2021
entrez:
2
3
2021
Statut:
ppublish
Résumé
The 11th KAIMRC Annual Research Forum Themed "COVID-19 Vaccine: Global Challenges and Prospects Forum" discussed COVID19 Vaccines. The Forum was a vital event as it provided a hub for leading COVID-19 vaccine scientists, regulators, developers, and distributors to learn about COVID-19 vaccines in development, make decisions about the best vaccines to use, and develop appropriate plans for global distribution and pricing. The COVID-19: Global Efforts for Development, Clinical Trials and Distribution Symposium brought together leading scientists, clinicians, pharma, decision makers, academic institutions and businesses to present and discuss the vaccines that are being currently developed for the COVID19. This event was held to shed light on these vaccines as many are at the late stage of Phase III clinical trials and ready to be marketed. This follows the confusion that few vaccines were produced and pushed into phase III without sharing all the necessary data preventing the scientific and clinical community to judge its efficacy and safety. This event allowed a discussion into the challenges in the distribution, pricing and accessibility of the vaccines. Moreover, the symposium discussed the importance to invest in Biotech-Pharma to combat and overcome any future health crisis. The discussion focused on Saudi Arabia leading initiatives as front runner in the field among G20 members.
Identifiants
pubmed: 33652065
pii: S1201-9712(21)00179-X
doi: 10.1016/j.ijid.2021.02.093
pmc: PMC7912554
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
448-451Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors report no declarations of interest.
Références
PLoS Negl Trop Dis. 2020 Jul 29;14(7):e0008548
pubmed: 32726304
Cell Death Differ. 2021 Feb;28(2):626-639
pubmed: 33479399
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Infect Genet Evol. 2020 Apr;79:104212
pubmed: 32004758
Nature. 2020 Sep;585(7824):174-177
pubmed: 32901123
Nature. 2020 Oct;586(7830):578-582
pubmed: 32731258
Cell. 2020 Aug 6;182(3):722-733.e11
pubmed: 32645327
Trans Am Clin Climatol Assoc. 2004;115:361-72; discussion 372-4
pubmed: 17060979
Nature. 2020 Aug;584(7819):115-119
pubmed: 32454513
Lancet. 2020 Sep 26;396(10255):887-897
pubmed: 32896291
N Engl J Med. 2020 Dec 10;383(24):2320-2332
pubmed: 32877576
N Engl J Med. 2020 Dec 17;383(25):2427-2438
pubmed: 32991794
Nature. 2020 Oct;586(7830):583-588
pubmed: 32731257
Nat Commun. 2020 May 20;11(1):2601
pubmed: 32433465